论文部分内容阅读
目的:比较聚乙二醇干扰素α-2a注射液和注射用重组人干扰素α1b在临床应用中对慢性丙型肝炎的治疗效果。方法:选取慢性丙型肝炎患者96例,分为试验A组和试验B组,分别进行聚乙二醇干扰素α-2a注射液和注射用重组人干扰素α1b治疗,治疗48周,对两组患者HCV-RNA转阴率、ALT复常率进行测定并比较两组患者在治疗过程中出现的不良反应,比较测定结果。结果:A组患者的HCV-RNA转阴率、ALT复常率较B组显示有优势,差异显著。结论:对聚乙二醇干扰素α-2a注射液和注射用重组人干扰素α1b在临床应用中对慢性丙型肝炎的治疗效果进行比较,两者有差异,且聚乙二醇干扰素α-2a注射液治疗效果较好,安全性高,值得推广。
Objective: To compare the therapeutic effect of peginterferon α-2a injection and recombinant human interferon α1b for chronic hepatitis C in clinical application. Methods: Ninety-six patients with chronic hepatitis C were selected and divided into experimental group A and experimental group B. The patients were treated with peginterferon alfa-2a injection and recombinant human interferon α1b injection for 48 weeks respectively. The negative rate of HCV-RNA and the normal rate of ALT in the group of patients were measured and the adverse reactions in the two groups were compared. The results were compared. Results: The negative rate of HCV-RNA and the rate of abnormal ALT in group A were superior to those in group B, and the difference was significant. Conclusion: The therapeutic effect of peginterferon α-2a injection and recombinant human interferon α1b for injection on chronic hepatitis C in clinical application are different, and there are differences between the two. Peginterferon α -2a injection treatment is better, high safety, it is worth promoting.